Abstract: Baclofen is often prescribed in high doses to fight cravings experienced by alcohol-dependent patients. Such an increase in the availability of baclofen is concerning. This study aimed to determine the change in number and profile of selfpoisoning with baclofen over time, as baclofen has become increasingly popular, in order to describe the severity of self-poisoning with baclofen and to focus on co-existing alcohol use disorders, and psychiatric illnesses determine predictors of severity. This was a retrospective study of self-poisoning with baclofen as reported by the western France Poison Control Center (PCC), which represents a population of more than 12 million people from
Craving is a key symptom in addiction. It is defined as a pressing, urgent and irrepressible desire to give in to an addictive behaviour, which usually results in loss of control [1] . This persistent symptom can arise spontaneously or be induced by exposing the individual to various stimuli related to the addictive behaviour through classical conditioning. Despite long periods of abstinence, cravings can reappear and increase the likelihood of relapse [1] [2] [3] . Special attention must therefore be paid in managing cravings during the treatment of an addicted individual. Current therapeutic approaches to alcohol use disorders (AUD) are most often based on psychotherapy. For more than 30 years, researchers have been developing methods for adjuvant care, particularly in the field of pharmacotherapy [4] . Unfortunately, the results of such trials have not been completely successful in meeting expectations [5] .
The lack of an effective treatment for the maintenance of abstinence from alcohol has led physicians to take an interest in baclofen. In Europe, baclofen has been prescribed for the maintenance of alcohol abstinence for the past several years in Switzerland and Belgium and more recently in Germany and Portugal, and many patient organizations have been created to promote that prescription. However, it was in France that the prescribing of baclofen is most prevalent. Besides Russia and France (since 2014), the prescribing of baclofen to treat addiction is still considered an 'off-label' use of the medication [for example unapproved by the Food and Drug Agency (USA), unapproved by the Medicines and Healthcare products Regulatory Agency (UK)].
Baclofen is a derivative of c-aminobutyric acid (GABA) and acts as a GABA receptor agonist, specifically on the GABA B receptors. Its beneficial effects result from the actions at spinal and supraspinal sites. The half-life of baclofen is variable, ranging from 4 hr at therapeutic doses up to more than 34.6 hr for doses of 450 mg/day [6] . The concentration ratio of cerebrospinal fluid (CSF)/plasma is 1-8. Baclofen is used to treat adults with muscle spasms that occur in cases of infectious and degenerative spinal disorders (e.g. multiple sclerosis, trauma, neoplasm) or central nervous system disorders (e.g. stroke). For these indications, the maximum dose per os is 120 mg/day, obtained by a titration of baclofen. The commonly prescribed doses are between 35 and 70 mg/day.
In the book 'The Last Glass' (2008), New York-based cardiologist of French origin, Olivier Ameisen, describes how he became indifferent to alcohol by taking baclofen daily at doses higher than normal [7] . A study (conducted by an American team) on the potential effects of baclofen on decreasing cocaine use [8, 9] led Olivier Ameisen, who suffered from alcohol dependence, to self-prescribe baclofen. Indeed, baclofen seemed to have addictolytic and anti-craving effects due to its action on the reward circuit. After demonstrating the effectiveness of baclofen in reducing alcohol consumption in rats [10, 11] , studies have tried to reproduce the same results in humans. The effective doses vary between studies: from 30 mg/day for some [12] [13] [14] [15] [16] [17] others [18, 19] . There is insufficient evidence to judge the efficacy of baclofen on the reduction in alcohol consumption. Two studies with a combined 81 participants, as reported in a 2015 Cochrane review, did not show any difference between baclofen versus placebo and baclofen versus diazepam in treating alcohol withdrawal syndrome. [20] . However, the unapproved prescribing of baclofen increased exponentially in France in 2008 [21, 22] . Since March 2014, the French drug agency [23] issued a 3-year temporary recommendation for the treatment of alcoholism with baclofen and authorized prescribing of baclofen for this indication at doses of up to 300 mg/day [24] . With regard to the tolerability of baclofen, there are currently very few studies on the toxic effects of the drug at high dosage. The adverse effects reported in the literature are mostly neurological and cardiovascular [25] [26] [27] [28] [29] [30] [31] . On a neurological level, baclofen depresses the central nervous system (CNS) and can cause coma, convulsions, agitation, abnormal electroencephalogram (EEG) with burst abolition and respiratory depression [32] [33] [34] . Cardiovascularly, it causes arterial hypotension or hypertension, bradycardia, rhythm disorders and lengthening of the QT interval [35] . There are few deaths from baclofen that have been reported in the literature [25, 36, 37] .
PCC are hospital departments whose missions are defined by the article L6141-4 of the French Public Health code. Poison centres are required to answer, especially in case of an emergency, any request for risk evaluation and any request for advice pertaining to the diagnosis, the prognosis and the treatment of human intoxications whether they be, accidental or voluntary, individual or collective, acute or not, provoked by any product or substance of natural or synthetic origin, available on the market or present in the environment (article L614-4 of the French Public Health code). These missions must be accomplished 24 hr a day (article D6141-39). In this context, doctors make telephone contact with poison centres when confronted with drug-related intoxications.
At the request of the national authorities, the French poison centres carried out a retrospective survey in alcohol-dependent patients to give an overview of baclofen exposure in this population [38] . Of the 294 observations of baclofen exposures in alcohol-dependent patients identified in the database, 220 were suicide attempts by self-poisoning and 74 were unintentional. The goal of our study was to focus on self-poisoning with baclofen in order to determine the change over time as baclofen has become a popular treatment for AUD and profile patients. We also compared the severity of poisoning regarding their medical history (psychiatric disorders, AUD, addiction, previous suicide attempts) to determine predictors of severity.
Materials and Methods
Design. A retrospective study listed all the calls received by the western France Poison Control Center (PCC) at Angers University Hospital that were related to exposures to self-poisoning with baclofen.
Sample and participants. The western France Poison Control Center usually receives notifications regarding a large number of poisoning cases that occur in four French regions, representing a population of more than 12 million people. A total of 58,000 calls are received each year, and the proportion of calls from physicians equals 56% (compared to 39% from the general public and 5% from nurses and paramedics).
This study was based on data collected by the Angers PCC during telephone responses to toxicological exposure and during patient follow-up, supplemented by reports from clinical staff in hospital. A case was defined as exposure to baclofen in self-harm attempt with or without symptoms.
Cases between January 2008 and March 2014 were reviewed. Data were extracted from the Poison Center database as authorized by the French data protection authority (Commission Nationale Informatique et Libert es, accreditation no. 747735). The personal data of patients were anonymized before their medical records were studied. Approval of the local Ethics Committee was unnecessary given the retrospective and non-interventional design of this study.
A data collection form was completed by one clinical toxicologist and reviewed by another clinical toxicologist.
Measures. For each selected case, all clinical variables were systematically collected and included:
1 The demographic characteristics of the patient: age, gender and background. 2 The circumstances surrounding the poisoning event: date and time of ingestion and estimated ingested dose (EID) (doses that the patients admitted to have ingested or the number of tablets deduced from the empty blisters found near them). The severity of poisoning was graded using a standardized scheme called Poison Severity Score (PSS) as follows [39] : none (grade 0), minor (grade 1), moderate (grade 2), severe and fatal (grade 3) poisoning. The PSS takes into account the most severe clinical features (e.g. cardiovascular, neurological, metabolic, respiratory symptoms) after follow-up. It allows a qualitative evaluation of morbidity and facilitates comparability of data.
Statistical analysis. Multivariate logistic regressions were performed with severity of self-poisoning cases as the dependent variable. (Y). Logistic regression applies when the binary response variable satisfies: Y = 1 when the case severity was grade 2,3 and Y = 0 when the case severity was grade 0,1. The model was evaluated using several statistical tests (Mainly Log-likelihood ratio test and the HosmerLemeshow test). In all tests, a p-value of <0.05 was considered as the threshold for significance. Statistical analysis was performed with SPSS software version 22 (SPSS Inc., Chicago, IL, USA).
Results
Time trends of baclofen self-poisoning. From January 2008 to March 2014 at Angers PCC, 111 cases of self-poisoning with baclofen were identified. They were divided into nine cases of 'null severity' (grade 0), 37 cases of 'minor severity' (grade 1), 19 cases of 'moderate severity' (grade 2) and 46 cases of 'high severity' (grade 3) with four deaths. During the same period, the Angers PCC identified 32,049 cases of drug self-poisoning, including 394 deaths.
An upward trend in the number of cases of self-poisoning with baclofen has been shown between 2008 and 2014.
Self-poisoning with baclofen accounted for one case in 2008 (0.3 of 1000 cases of voluntary intoxication of all agents), increasing to 39 cases in 2013 (14 of 1000 cases). Meanwhile, cases with AUD were found to follow the same trend (25 cases; nine of 1000 cases), while patients with neurological history in 2013 represented only eight cases (three of 1000 cases) ( fig. 1 ). At Angers PCC over the same period, the number of cases of self-poisoning with all medicines was stable.
Clinical presentation and severity of the cases. The EID of baclofen was known in 89 cases (80%). The average EID was 325 mg with a range between 10 and 3100 mg and a median value of 300 mg. For severe cases, the EID of baclofen was known in 29 cases (63%). The average EID was 725 mg with a range between 35 and 3100 mg, with a median value of 600 mg.
In all cases, the average number of co-agents was 3.3. In 33 cases, baclofen was the only agent used. It was associated with alcohol in 34 cases, with an average blood alcohol level of 0.43 g/l, ranging from 0.10 to 2.9 g/l. Anxiolytics were the main co-agents associated with baclofen ( fig. 2 ). The repartition of these co-ingestions was stable during the period of the study.
The symptoms reported in cases of minor and moderate severity were predominantly neurological: coma with a Glasgow Coma Score (GS) between 10 and 14, cerebellar syndrome and convulsions. Psychiatric disorders (agitation, hallucinations), cardiovascular symptoms (tachycardia, arterial hypotension) and gastrointestinal symptoms (nausea, vomiting) were also noted. All clinical signs are summarized in table 1.
According to the clinical analysis of the high severity cases, the most frequently reported symptoms were neurological (45%) and cardiovascular (27%). Neurological symptoms were manifested by coma (GS ≤ 8), agitation and seizures. An EEG was carried out in four patients. For one patient, an abnormal unspecified trace was identified. For another patient, a slow trace with paroxysmal discharge activity was identified and for two other patients, a burst abolition trace. The main cardiovascular symptoms observed were arterial hypotension, bradycardia and lengthening of the QTc interval. Other symptoms experienced were hypothermia (8%) and bradypnoea (4%), as well as complications resulting from a coma, such as aspiration pneumonia (7%) and rhabdomyolysis (6%).
The management of these poisonings was conducted in an ICU in 43 cases and in a conventional service in one case, while two cases were not supported, with death occurring at home. The residence time of the patients was known in 30 cases, with an average of 7 days and a range of 2-50 days. During treatment, 39 patients required tracheal intubation. The clinical outcome was favourable in 42 cases, while the number of deaths recorded was 4. As soon as their condition allowed, the patients were interviewed by a psychiatrist in charge of assessing suicidal intentionality. The use of suicide intent scales is common in this type of interview.
In 2010, a 51-year-old woman's death was reported. During her stay in hospital, she presented with a coma GS 3 and a hypotension of 60/40 mmHg. This serious intoxication was complicated by rhabdomyolysis, aspiration pneumonia and seizures. She died after 50 days in intensive care. In this case, the baclofen blood test was not conducted, but the toxicological analysis showed plasma concentrations of digoxin and benzodiazepines within therapeutic limits. The second death occurred in 2013 involving a man found in cardiac arrest at his home. He was initially resuscitated by firefighters but died 10 days after treatment began. He was being treated with baclofen for multiple sclerosis. He presented with a coma GS 3, combined with seizures, low blood pressure (systolic blood pressure of 50 mmHg) and hypothermia at 32°C. Toxicology screening showed no urinary tricyclic, phenobarbital and benzodiazepines. The third death occurred in 2013 and involved a 48-year-old man who had a history of AUD, for which he was treated with baclofen. He was found dead at his home 16 days after the renewal of baclofen. Beside the body were seven empty boxes of baclofen (2.1 g total), oxazepam and four empty bottles of alcoholic beverages. Assays were performed revealing a blood alcohol concentration (BAC) of 0.2 g/l and a baclofen level of 2.7 mg/l and 81 mg/l in blood and urine respectively. The fourth death occurred in 2013 in a 34-year-old patient who was treated with baclofen for an AUD. He was found dead at his home. Baclofen boxes were found in the bin. The assays performed in blood showed zero alcohol and baclofen at 14.8 mg/l.
Medical history and severity of cases.
This series included 62 men and 49 women with a gender ratio of 1.3. The average age was 39 AE 12. The indication of baclofen was known in 84 of 111 cases (76%): treatment of alcohol dependence 73%; neurological indication 17% and other indication (eating disorders, other addiction) 10%.
The most common patient histories were AUD (55%) and psychiatric disorders (50%). In 32 cases (27%), patients had a history of both AUD and psychiatric disorders. The proportion of patients with AUD increased from 2008 to 2013. Other reported antecedents were neurological disorders (17%) and other substance abuse disorders (14%). Thirty-one patients (28%) had previously attempted suicide ( fig. 3) .
Multivariate logistic regressions were performed with severity of self-poisoning (table 2) .
Psychiatric disorders significantly increased severity of cases (adjusted OR = 2.9; p = 0.03). Addiction history also significantly increased severity of cases (adjusted OR = 5.8; p = 0.02).
Alcohol use disorders seems to increase severity of cases (OR = 2.0; p = 0.17), although it is not statistically significant.
Discussion
The goal of this study was to describe the different aspects of self-poisoning with baclofen, including clinical data, prescription context, patient characteristics and risk factors of severe intoxication from 1 January 2008 (publication of Ameisen's book 'The Last Glass') to 1 March 2014 (before the beginning of the Temporary Recommendation for Use (TRU)). 1 Grade 0 (n = 9) no adverse effect observed. The study shows that cases of self-poisoning with baclofen in an attempt to commit suicide are on the rise. In fact, selfpoisoning accounted for 0.3 of 1000 cases of voluntary intoxication of all agents in 2008 and for 15 of 1000 cases in 2013. The study also reveals an increase in the number of cases of severe intoxication involving baclofen. This high increase is consistent with the results of the French PCC national reports [21, 38] .
Minor and moderate poisoning (grade 1 or 2) were associated with psychiatric symptoms (such as unrest and hallucinations) and neurological signs (such as depression of the central nervous system). Our series included a high proportion of cases of severe poisoning (grade 3 = 41%). The neurological (45%) and cardiovascular (27%) symptoms mainly found in our study were similar to those described in the literature [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . In cases of baclofen poisoning, the neurological toxic effects, in particular, may become life-threatening. Baclofen is a pro-convulsant drug which increases neural excitation contrast in some parts of the brain [40] . As shown in our series, self-poisoning with baclofen in alcohol-dependent patients was frequently associated with alcohol and benzodiazepines. Physicians should be warned before using antidotes such as flumazenil, which may cause seizures. The clinical analysis is difficult to establish, given that few assays are performed in current clinical practices. The interest of an assay can be underestimated by the clinician because it does not change the therapeutic approach [41] . Moreover, baclofen determination in plasma needs a specific method [42] . There are still few toxicology laboratories that perform assays, but the detection technique is becoming more common. Hence clinicians, toxicologists and biologists must work together in order to document the intoxications and thus improve clinico-analytical knowledge and health monitoring.
Our study described four deaths (3.6% of cases). To date, only a few cases of death caused by baclofen have been reported in the literature [25, 36, 37] . Most of the deaths discussed in the study occurred before the patient was admitted to hospital. Medical treatment at an early stage could therefore limit or even remove the risk of death.
For the reported cases, the assumed ingested doses were not known and the lethal concentrations ranged from 6 to 17 mg/l [37] . The therapeutic concentration was <0.6 mg/l. In the third case, the blood level of baclofen was less than the lethal levels found in the literature. The case was attributed to baclofen in the light of the lack of any other drug found during testing. Indeed, it has been subjected to a toxicological screening which makes it possible to search qualitatively or semi-quantitatively most of the toxicants involved in suicides: benzodiazepines, barbiturates, antidepressants, etc.
Baclofen was ingested alone or in conjunction with alcohol in almost half of the cases, while most cases of voluntary drug intoxication involve several drugs [43] . When other drugs were found, they were usually anxiolytics, present in large quantities. Otherwise, there is appreciable misuse of GABAanalogue medications such as baclofen, gabapentin and pregabalin in European countries (e.g. UK). We observed similar craving behaviour with GABA-analogue medication : a tolerance phenomenon and a withdrawal syndrome. GABAanalogue medications misuse may be a cause for concern, especially in patients with a history of substance misuse [44] . The origin of most of misuse appears to be from sources other than legitimately prescribed medication, which has important implications for future strategies to reduce access to these medications. It is of course crucial that these ingestions of multiple drugs be brought to the attention of the prescriber upon the patient's treatment, seeing as they can worsen the clinical picture presented.
In our study, voluntary baclofen poisoning was predominant among men and the average age was 39 years. An earlier study, which was aimed at defining populations at risk of alcohol misuse, found the same trends [38] . Reversing the trends in the proportion of alcohol-dependent patients and patients with neurological conditions reflects the indications shift in prescription of baclofen in France. The indication of baclofen with the aim of maintaining the abstinence from alcohol was well above the initial neurological indication.
Furthermore, we were interested in a possible link between the patient's psychiatric history and their turning-to-suicide by baclofen. Indeed, depressed, alcohol-dependent patients are more likely to attempt suicide than non-depressed alcoholdependent individuals [45] . Studies have shown a strong link between addictive and psychiatric disorders. According to the Epidemiologic Catchment Area study, 37% of people with an AUD also suffer from a psychiatric disorder [46] . AUD is a well-known risk factor for attempted suicide [47] , necessitating emergency admission, and co-occurs with a life-time prevalence of roughly 50% in people with bipolar disorder [48] . Life-time co-occurrence of an alcohol use disorder and an anxiety disorder ranges from 6 to 20% depending on the specific type of anxiety disorder (e.g. social anxiety disorder, generalized anxiety disorder, obsessive compulsive disorder or post-traumatic stress disorder) [49] . This comorbidity rate reached 52% in the National Comorbidity Survey [49] . Between psychiatric comorbidities and alcohol consumption, the profile of alcohol-dependent patients is unique. Alcohol in particular poses a risk of panic disorder and bipolar disorder [50] . Furthermore, addicts are characterized by a high level of impulsivity [51] . Impulsivity and psychiatric disorders are well known to be major risks of suicide, which could explain premature mortality among people with dual diagnoses [52] . A connection has been found between alcohol use, impulsiveness and risk of suicide [53] . The particular profile of people with AUD may encourage voluntary overdose; the prescriber should therefore be vigilant. The risk of suicide attempt is highest during alcohol intoxication due to disinhibition and impaired judgment, but also exists during the withdrawal phase due to attentional and inhibitory dysfunction and persists further throughout the abstinence phase in case of poor relationships [54] . The prescribed treatment requires regular reassessment in order to detect both a severe major depression, a current risk of suicide, the toxicity and any misuse. Currently, the addition of antidepressant treatment is recommended with a persistence of depressive symptoms present a month after withdrawal.
In addition to revealing an increased risk of suicide, our series shows a significant relationship between the severity of self-poisoning with baclofen and patients' histories concerning psychiatric disorders and substance use dependence. In our series, not only did 50% of patients have a history of psychiatric disorders, but we also found that psychiatric disorders significantly increased (OR = 2.9; p = 0.03) the risk of suffering from a high severity grade of self-poisoning with baclofen. This is the same for patients with substance abuse, risk of suffering from a high severity grade of self-poisoning with baclofen increased significantly (OR = 5.8; p = 0.02).
Despite its determination to monitor the amount of baclofen prescribed, the French National Agency for Medicines and Health Products Safety (ANSM) recognizes that the majority of prescriptions were outside the framework of the TRU. In October 2015, the ANSM published a summary concerning the first 6 months of the TRU; 6200 patients were registered and 45% of prescribers were general practitioners, but more than 100,000 people took baclofen to treat their alcohol dependence [37] . An indication of maintaining abstinence from alcohol has become the main reason for prescribing baclofen. Recently, four studies on baclofen were presented at the congress of international and European biomedical research societies on alcoholism (ISBRA/ESBRA congressBerlin -2-5 December 2015) and showed negative results.
Some authors have described severe poisoning resulting from baclofen administered in doses authorized by the TRU [25, 26, 28, 30] . Moreover, with doses authorized by the TRU reaching up to 300 mg/day [24] (i.e. one box of 30 tablets per day or 9 g of baclofen per month) patients have access to a potentially high quantity of baclofen tablets, of which its ingestion in mass amounts can have severe or even lethal consequences, as demonstrated in this study. In this context, giving baclofen a specific dispensing status may help decrease the risks (administration of small doses, authorization for its debottling).
Healthcare authorities should consider a new policy for prescribing baclofen with regard to alcohol dependence treatment, as recommended above. It is important to note that prescribing baclofen should not exclude psychological and social care, which combine to complete medicinal treatment [42] . The aim is to offer complete and multi-disciplinary care and refrain from the overprescribing of baclofen by prescribers who consider this to be a miracle solution.
